File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY

TitleHBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY
Authors
Issue Date26-Sep-2023
PublisherElsevier
Citation
Gastroenterology, 2023 How to Cite?
Abstract

Background & aims. Patients who discontinue nucleo(s)tide analogue (NUC) therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment followup. Methods. We studied the association between HBsAg and HBV DNA levels at off-treatment FU W24 with subsequent clinical relapse and HBsAg loss was in a multicentre cohort of HBeAg negative chronic hepatitis B patients who discontinued NUC therapy. Results. We studied 475 patients, 82% Asian and 55% treated with entecavir. Patients with higher HBV DNA levels at FU W24 had a higher risk of clinical relapse (hazard ratio [HR] 1.576, p100 IU/mL and HBV DNA >100 IU/mL (p<0.001). Conclusions. Among HBeAg negative CHB patients who discontinued antiviral therapy and who did not experience clinical relapse before FU W24, serum levels of HBV DNA and HBsAg at FU W24 can be used to predict subsequent clinical relapse and HBsAg clearance. A combination of HBsAg <100 IU/mL with HBV DNA <100 IU/mL identifies patients with a low risk of relapse and excellent chances of HBsAg loss, and could potentially be used as an early surrogate endpoint for studies aiming at finite therapy in HBV.


Persistent Identifierhttp://hdl.handle.net/10722/337401
ISSN
2023 Impact Factor: 25.7
2023 SCImago Journal Rankings: 7.362

 

DC FieldValueLanguage
dc.contributor.authorSonneveld, MJ-
dc.contributor.authorChiu, S-M-
dc.contributor.authorPark, JY-
dc.contributor.authorBrakenhoff, SM-
dc.contributor.authorKaewdech, A-
dc.contributor.authorSeto, WK-
dc.contributor.authorTanaka, Y-
dc.contributor.authorCarey, I-
dc.contributor.authorPapatheodoridi, M-
dc.contributor.authorColombatto, P-
dc.contributor.authorVan Bömmel, F-
dc.contributor.authorJanssen, HL-
dc.contributor.authorBerg, T-
dc.contributor.authorZoulim, F-
dc.contributor.authorAhn, SH-
dc.contributor.authorDalekos, GN-
dc.contributor.authorErler, NS-
dc.contributor.authorBrunetto, M-
dc.contributor.authorWedemeyer, H-
dc.contributor.authorCornberg, M-
dc.contributor.authorYuen, MF-
dc.contributor.authorAgarwal, K-
dc.contributor.authorBoonstra, A-
dc.contributor.authorButi, M-
dc.contributor.authorPiratvisuth, T-
dc.contributor.authorPapatheodoridis, G-
dc.contributor.authorChen, C-H-
dc.contributor.authorMaasoumy, B-
dc.date.accessioned2024-03-11T10:20:35Z-
dc.date.available2024-03-11T10:20:35Z-
dc.date.issued2023-09-26-
dc.identifier.citationGastroenterology, 2023-
dc.identifier.issn0016-5085-
dc.identifier.urihttp://hdl.handle.net/10722/337401-
dc.description.abstract<p>Background & aims. Patients who discontinue nucleo(s)tide analogue (NUC) therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment followup. Methods. We studied the association between HBsAg and HBV DNA levels at off-treatment FU W24 with subsequent clinical relapse and HBsAg loss was in a multicentre cohort of HBeAg negative chronic hepatitis B patients who discontinued NUC therapy. Results. We studied 475 patients, 82% Asian and 55% treated with entecavir. Patients with higher HBV DNA levels at FU W24 had a higher risk of clinical relapse (hazard ratio [HR] 1.576, p100 IU/mL and HBV DNA >100 IU/mL (p<0.001). Conclusions. Among HBeAg negative CHB patients who discontinued antiviral therapy and who did not experience clinical relapse before FU W24, serum levels of HBV DNA and HBsAg at FU W24 can be used to predict subsequent clinical relapse and HBsAg clearance. A combination of HBsAg <100 IU/mL with HBV DNA <100 IU/mL identifies patients with a low risk of relapse and excellent chances of HBsAg loss, and could potentially be used as an early surrogate endpoint for studies aiming at finite therapy in HBV. <br></p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofGastroenterology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleHBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY-
dc.typeArticle-
dc.identifier.doi10.1053/j.gastro.2023.09.033-
dc.identifier.eissn1528-0012-
dc.identifier.issnl0016-5085-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats